CytoDyn Inc. (CYDY)
OTCMKTS: CYDY · Delayed Price · USD
0.155
+0.004 (2.75%)
Apr 19, 2024, 3:59 PM EDT - Market closed

Company Description

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications.

The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.

The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CytoDyn Inc.
Country WA
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Dr. Jacob P. Lalezari M.D.

Contact Details

Address:
1111 Main Street, Suite 660
Vancouver, Washington 98660
United States
Phone 360-980-8524
Website cytodyn.com

Stock Details

Ticker Symbol CYDY
Exchange OTCMKTS
Fiscal Year June - May
Reporting Currency USD
CIK Code 0001175680
CUSIP Number 23283M101
ISIN Number US23283M1018
Employer ID 75-3056237
SIC Code 2834

Key Executives

Name Position
Dr. Cyrus Arman M.B.A., Ph.D. Senior Vice President of Business Operations
Dr. Jacob P. Lalezari M.D. Chief Executive Officer and Member of Scientific Advisory Board
Mitchell Cohen Interim Chief Financial Officer
Tyler Blok Executive Vice President of Legal Affairs and Secretary
Dr. Scott Hansen Ph.D. Head of Research and Basic Science
Joseph Meidling Executive Director of Clinical Operations
Cristina De Leon Investors

Latest SEC Filings

Date Type Title
Apr 16, 2024 424B3 Prospectus
Apr 16, 2024 424B3 Prospectus
Apr 15, 2024 10-Q Quarterly Report
Apr 8, 2024 424B3 Prospectus
Apr 8, 2024 424B3 Prospectus
Apr 8, 2024 8-K Current Report
Mar 28, 2024 8-K Current Report
Mar 1, 2024 424B3 Prospectus
Mar 1, 2024 424B3 Prospectus
Feb 22, 2024 424B3 Prospectus